Debra Richardson to Retrospective Studies
This is a "connection" page, showing publications Debra Richardson has written about Retrospective Studies.
Connection Strength
0.693
-
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
Score: 0.096
-
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016 Mar; 127(3):468-473.
Score: 0.081
-
Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012 Oct; 127(1):43-6.
Score: 0.063
-
Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar; 124(3):508-11.
Score: 0.060
-
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
Score: 0.048
-
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
Score: 0.048
-
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747.
Score: 0.028
-
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020 03; 156(3):568-574.
Score: 0.027
-
The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol. 2018 12; 41(12):1225-1230.
Score: 0.025
-
Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2018 05; 41(5):447-451.
Score: 0.024
-
The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2018 Apr; 223:108-112.
Score: 0.023
-
Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
Score: 0.021
-
Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5.
Score: 0.019
-
Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. J Reprod Med. 2015 May-Jun; 60(5-6):243-8.
Score: 0.019
-
Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5.
Score: 0.018
-
Factors associated with clinical trial screening failures in gynecologic oncology. Gynecol Oncol. 2014 Sep; 134(3):450-4.
Score: 0.018
-
Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9.
Score: 0.018
-
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
Score: 0.017
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
Score: 0.014
-
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
Score: 0.014
-
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
Score: 0.013